U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Diminished ability to concentrate

MedGen UID:
65900
Concept ID:
C0235198
Finding
Synonyms: Concentration difficulties; Lack of concentration
SNOMED CT: Unable to concentrate (60032008)
 
HPO: HP:0031987

Definition

Being unable to focus one's attention or mental effort on a particular object or activity. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVDiminished ability to concentrate

Conditions with this feature

Craniosynostosis 4
MedGen UID:
322167
Concept ID:
C1833340
Disease or Syndrome
Craniosynostosis (CRS) is a primary abnormality of skull growth involving premature fusion of the cranial sutures such that the growth velocity of the skull often cannot match that of the developing brain. This produces skull deformity and, in some cases, raises intracranial pressure, which must be treated promptly to avoid permanent neurodevelopmental disability (summary by Fitzpatrick, 2013). Craniosynostosis-4 (CRS4) includes lambdoid, sagittal, metopic, coronal, and multisuture forms. For a discussion of genetic heterogeneity of craniosynostosis, see CRS1 (123100).
Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis
MedGen UID:
375302
Concept ID:
C1843851
Disease or Syndrome
POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations
MedGen UID:
348124
Concept ID:
C1860518
Disease or Syndrome
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a small-vessel disease that affects highly vascularized tissues including the retina, brain, liver, and kidneys. Age of onset is often between 35 and 50 years. The most common presenting finding is decreased visual acuity and/or visual field defects. Neurologic manifestations may include hemiparesis, facial weakness, aphasia, and hemianopsia. Migraines and seizures are less frequently described. Renal manifestations may include mild-to-moderate increase in serum creatinine and mild proteinuria; progression to end-stage renal disease (ESRD) is uncommon. Hepatic manifestations frequently include mildly elevated levels of alkaline phosphatase and gamma-glutamyltransferase (GGT). Less common findings include psychiatric disorders, hypertension, mild-to-moderate anemia, and Raynaud phenomenon.
Chromosome 6q24-q25 deletion syndrome
MedGen UID:
461565
Concept ID:
C3150215
Disease or Syndrome
6q25 microdeletion syndrome is a recently described syndrome characterized by developmental delay, facial dysmorphism and hearing loss.
Chromosome 15q11.2 deletion syndrome
MedGen UID:
467404
Concept ID:
C3180937
Disease or Syndrome
A heterozygous deletion of chromosome 15q11.2 may increase the susceptibility to neuropsychiatric or neurodevelopmental problems, including delayed psychomotor development, speech delay, autism spectrum disorder, attention deficit-hyperactivity disorder, obsessive-compulsive disorder, and possibly seizures (summary by Doornbos et al., 2009 and Burnside et al., 2011). See also chromosome 15q11.2 duplication syndrome (608636).
Developmental delay with autism spectrum disorder and gait instability
MedGen UID:
816083
Concept ID:
C3809753
Disease or Syndrome
Developmental delay with autism spectrum disorder and gait instability is a rare, genetic, neurological disorder characterized by infant hypotonia and feeding difficulties, global development delay, mild to moderated intellectual disability, delayed independent ambulation, broad-based gait with arms upheld and flexed at the elbow with brisk walking or running, and limited language skills. Behavior patterns are highly variable and range from sociable and affectionate to autistic behavior.
Hypothyroidism, congenital, nongoitrous, 8
MedGen UID:
1684717
Concept ID:
C5231395
Disease or Syndrome
Congenital nongoitrous hypothyroidism-8 (CHNG8) is characterized by relatively mild central hypothyroidism, which may be accompanied by hearing loss in some patients (Heinen et al., 2016).
Neurodevelopmental disorder with dysmorphic facies and variable seizures
MedGen UID:
1784197
Concept ID:
C5543268
Disease or Syndrome
Neurodevelopmental disorder with dysmorphic facies and variable seizures (NEDDFAS) is an autosomal recessive disorder characterized by global developmental delay apparent in early childhood. Patients have mildly impaired intellectual development, often with speech delay or behavioral abnormalities. Some may have seizures. Most have nonspecific dysmorphic facial features. Additional findings may include brain imaging abnormalities, mild skeletal defects, and renal abnormalities, although the renal anomalies may be unrelated (summary by Shao et al., 2021).
Developmental delay, impaired speech, and behavioral abnormalities
MedGen UID:
1794167
Concept ID:
C5561957
Disease or Syndrome
Developmental delay, impaired speech, and behavioral abnormalities (DDISBA) is characterized by global developmental delay apparent from early childhood. Intellectual disability can range from mild to severe. Additional variable features may include dysmorphic facial features, seizures, hypotonia, motor abnormalities such as Tourette syndrome or dystonia, and hearing loss (summary by Cousin et al., 2021).
Chromosome Xq13 duplication syndrome
MedGen UID:
1809227
Concept ID:
C5677057
Disease or Syndrome
Leukodystrophy, hypomyelinating, 25
MedGen UID:
1840911
Concept ID:
C5830275
Disease or Syndrome
Hypomyelinating leukodystrophy-25 (HLD25) is an autosomal recessive disorder characterized by horizontal nystagmus, hypotonia, and global developmental delay apparent soon after birth or in infancy. Most patients show gradual clinical improvement over time with resolution of the nystagmus in early childhood. Many achieve developmental milestones and may have normal cognition, although the severity of the disorder varies and some patients may have persistent neurologic deficits, such as ataxia or intellectual disability. Brain imaging shows hypomyelination that may also improve with time (Yan et al., 2022; do Rosario et al., 2022). For a general phenotypic description and a discussion of genetic heterogeneity of HLD, see 312080.

Professional guidelines

PubMed

Usmani K, Jain SK, Yadav S
J Ethnopharmacol 2023 Dec 5;317:116828. Epub 2023 Jun 25 doi: 10.1016/j.jep.2023.116828. PMID: 37369335
Gigante A, Callegari L
Rheumatol Int 2011 Apr;31(4):427-44. Epub 2010 Nov 28 doi: 10.1007/s00296-010-1660-6. PMID: 21113807
Griffiths P
Eur J Pediatr 2000 Oct;159 Suppl 2:S82-6. doi: 10.1007/pl00014390. PMID: 11043151

Recent clinical studies

Etiology

Loetscher T, Potter KJ, Wong D, das Nair R
Cochrane Database Syst Rev 2019 Nov 10;2019(11) doi: 10.1002/14651858.CD002842.pub3. PMID: 31706263Free PMC Article
Popa-Velea O, Bubulac L, Petrescu L, Purcarea RM
J Med Life 2016 Oct-Dec;9(4):328-333. PMID: 27928433Free PMC Article
Nath KA, Hebbel RP
Nat Rev Nephrol 2015 Mar;11(3):161-71. Epub 2015 Feb 10 doi: 10.1038/nrneph.2015.8. PMID: 25668001Free PMC Article
Suarez-Rivera M, Bonilla-Felix M
Curr Pediatr Rev 2014;10(2):115-22. doi: 10.2174/157339631002140513102053. PMID: 25088265
Gigante A, Callegari L
Rheumatol Int 2011 Apr;31(4):427-44. Epub 2010 Nov 28 doi: 10.1007/s00296-010-1660-6. PMID: 21113807

Diagnosis

Emhoff CW, Messonnier LA
Nutrients 2023 Jul 20;15(14) doi: 10.3390/nu15143213. PMID: 37513631Free PMC Article
Fan L, Kong X, Zhang P, Lin P, Zhao J, Ji X, Fang S, Wang X, Yao S, Li H, Wang X
J Affect Disord 2021 Dec 1;295:1421-1431. Epub 2021 Sep 17 doi: 10.1016/j.jad.2021.09.019. PMID: 34563390
Suarez-Rivera M, Bonilla-Felix M
Curr Pediatr Rev 2014;10(2):115-22. doi: 10.2174/157339631002140513102053. PMID: 25088265
López B, González A, Querejeta R, Díez J
J Hypertens 2005 Aug;23(8):1445-51. doi: 10.1097/01.hjh.0000173780.67308.f1. PMID: 16003166
Hartwig A
Toxicol Lett 1998 Dec 28;102-103:235-9. doi: 10.1016/s0378-4274(98)00312-9. PMID: 10022259

Therapy

Usmani K, Jain SK, Yadav S
J Ethnopharmacol 2023 Dec 5;317:116828. Epub 2023 Jun 25 doi: 10.1016/j.jep.2023.116828. PMID: 37369335
Schilling AL, Cannon E, Lee SE, Wang EW, Little SR
Biomaterials 2022 Mar;282:121430. Epub 2022 Feb 18 doi: 10.1016/j.biomaterials.2022.121430. PMID: 35202932
Loetscher T, Potter KJ, Wong D, das Nair R
Cochrane Database Syst Rev 2019 Nov 10;2019(11) doi: 10.1002/14651858.CD002842.pub3. PMID: 31706263Free PMC Article
Ren X, St Clair DK, Butterfield DA
Pharmacol Res 2017 Mar;117:267-273. Epub 2017 Jan 4 doi: 10.1016/j.phrs.2017.01.001. PMID: 28063894
Richardson DW, Robinson AG
Ann Intern Med 1985 Aug;103(2):228-39. doi: 10.7326/0003-4819-103-2-228. PMID: 3893256

Prognosis

Gul M, Hildorf S, Dong L, Thorup J, Hoffmann ER, Jensen CFS, Sønksen J, Cortes D, Fedder J, Andersen CY, Goossens E
Hum Reprod Update 2020 Apr 15;26(3):368-391. doi: 10.1093/humupd/dmaa003. PMID: 32163572
Galleano M, Verstraeten SV, Oteiza PI, Fraga CG
Arch Biochem Biophys 2010 Sep 1;501(1):23-30. Epub 2010 Apr 11 doi: 10.1016/j.abb.2010.04.005. PMID: 20388486
Zhou XJ, Saxena R, Liu Z, Vaziri ND, Silva FG
Int Urol Nephrol 2008;40(3):823-39. Epub 2008 Jun 27 doi: 10.1007/s11255-008-9405-0. PMID: 18584301
Colomer R, Menéndez JA
Clin Transl Oncol 2006 Jan;8(1):15-21. doi: 10.1007/s12094-006-0090-0. PMID: 16632435
Desta Z, Zhao X, Shin JG, Flockhart DA
Clin Pharmacokinet 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002. PMID: 12222994

Clinical prediction guides

He J, Chuang CY, Hawkins CL, Davies MJ, Hägglund P
Free Radic Biol Med 2023 Sep;206:83-93. Epub 2023 Jun 28 doi: 10.1016/j.freeradbiomed.2023.06.028. PMID: 37385567
Ahmad T, Valentovic MA, Rankin GO
Biochem Pharmacol 2018 Jul;153:196-204. Epub 2018 Feb 16 doi: 10.1016/j.bcp.2018.02.020. PMID: 29458047Free PMC Article
Ziemba B, Matuszko G, Bryszewska M, Klajnert B
Cell Mol Biol Lett 2012 Mar;17(1):21-35. Epub 2011 Nov 16 doi: 10.2478/s11658-011-0033-9. PMID: 22086186Free PMC Article
Galleano M, Verstraeten SV, Oteiza PI, Fraga CG
Arch Biochem Biophys 2010 Sep 1;501(1):23-30. Epub 2010 Apr 11 doi: 10.1016/j.abb.2010.04.005. PMID: 20388486
Martin-Soelch C
Biochem Soc Trans 2009 Feb;37(Pt 1):313-7. doi: 10.1042/BST0370313. PMID: 19143654

Recent systematic reviews

Loetscher T, Potter KJ, Wong D, das Nair R
Cochrane Database Syst Rev 2019 Nov 10;2019(11) doi: 10.1002/14651858.CD002842.pub3. PMID: 31706263Free PMC Article
Loetscher T, Lincoln NB
Cochrane Database Syst Rev 2013 May 31;2013(5):CD002842. doi: 10.1002/14651858.CD002842.pub2. PMID: 23728639Free PMC Article
Kurth E, Kennedy HP, Spichiger E, Hösli I, Stutz EZ
Midwifery 2011 Apr;27(2):187-94. Epub 2009 Sep 20 doi: 10.1016/j.midw.2009.05.012. PMID: 19773102

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...